Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies (original) (raw)

Additional Information:

The study’s coordinating centre has been underpinned by grants G0800270 and MR/L003120/1 from the UK Medical Research Council, grants SP/09/002, RG/08/014, and RG13/ 13/30194 from the British Heart Foundation, grants from the National Institute for Health Research through the Cambridge Biomedical Research Centre, grant HEALTH-F2-2012-279233 from the European Commission Framework 7 through the EPIC-CVD award, and grants from the European Research Council through an Advanced Investigator Award 268834 to Dr Danesh. Dr Burgess is supported by a Sir Henry Dale Fellowship jointly funded by theWellcome Trust and the Royal Society (grant number 204623/Z/16/Z). Dr Danesh holds a BHF Professorship and NIHR Senior Investigator Award. Aspects of the analysis were supported by the Cambridge Substantive Site of Health Data Research UK.

Authors:

Burgess, S., Ference, B. A., Staley, J. R., Freitag, D. F., Mason, A. M., Nielsen, S. F., Willeit, P., Young, R., Surendran, P., Karthikeyan, S., Bolton, T. R., Peters, J. E., Kamstrup, P. R., Tybjærg-Hansen, A., Benn, M., Langsted, A., Schnohr, P., Vedel-Krogh, S., Kobylecki, C. J., Ford, I., Packard, C., Trompet, S., Jukema, J. W., Sattar, N., Di Angelantonio, E., Saleheen, D., Howson, J. M. M., Nordestgaard, B. G., Butterworth, A. S., and Danesh, J.

Publisher:

American Medical Association

First Published:

First published in JAMA Cardiology 3(7):619-627

Publisher Policy:

Reproduced under a Creative Commons License